Search academic texts

Information × Registration Number 0224U031712, 0122U001817 , R & D reports Title Development of new compounds for diagnostic and therapeutic applications in nuclear medicine and treatment of malignant tumors popup.stage_title Head Lampeka Rostyslav D., Доктор хімічних наук Registration Date 06-06-2024 Organization Taras Shevchenko National University of Kyiv popup.description2 This stage is dedicated to establishing the structure of the obtained compounds and studying their physical properties, in particular magnetic, optical and biological. New 24 complexes have been synthesized and fully characterized by means of spectroscopy, and x-ray crystallography. Based on crystallographic data, all parameters of bond lengths and angles, types of intermolecular (supramolecular) interactions (hydrogen, π-π-stacking etc.) were determined. Connections between the chemical composition and the structural compound, and the corresponding functional properties have been established as well. Copper (II) complexes with 1,2,4-triazoles were investigated for magnetic properties. Magnetic susceptibility was analyzed for six different coordination compounds, which made it possible to explain the nature of magnetic interactions in the compounds. All complexes reveal antiferromagnetic properties. The anticancer potential of 20 complexes of platinum (II), palladium (II) and ruthenium (II) with 2-(1H-1,2,4-triazol-3-yl)pyridine derivatives was studied. The in vitro cytotoxic activity was studied against a panel of five different cancer cell lines using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide) and resazurin assay. MTT and resazurin assay are the commonly used tests to quantify the number of live cells in a sample, and to monitor cell viability / cytotoxicity. It was observed that Platinum (II) and Palladium (II) complexes bearing bifunctionalized 2-(1H-1,2,4-triazole-3-yl)pyridines exhibited significant cytotoxicity, specially on SK-N-DZ and Jurkat cell lines. The best results were afforded for two compound, the IC50 values of whiсh were 5 and 15 times lower in comparision to cisplatin values, respectively.  Product Description popup.authors Ivanova Hanna V. Vashchenko Oleksandr V. Doroschuk Roman O. Zakharchenko Borys V. Plutenko Maksym O. Raspertova Іlona V. Khomenko Dmytro M. popup.nrat_date 2024-06-06 Close